Compare KKR & Co Inc (KKR) vs Repligen Corporation Common Stock (RGEN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
KKR & Co Inc vs Repligen Corporation Common Stock — how do they compare? KKR & Co Inc trades at $85.5 (market cap $78.24B), while Repligen Corporation Common Stock trades at $178.15 (market cap $11.14B). The key difference: KKR & Co Inc is far larger — about 7× Repligen Corporation Common Stock's market cap, and KKR & Co Inc pays a 0.89% dividend while Repligen Corporation Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold KKR & Co Inc for 67 Days and Repligen Corporation Common Stock for 0 Days on average.
| KKR | RGEN | |
|---|---|---|
Market Cap | $78.24B | $11.14B |
Volume | 9,217,096 | 1,259,263 |
Sector | Financials | Health |
52-Week High | $142.75 | $194.57 |
52-Week Low | $83.88 | $102.87 |
Typical Hold Time | 67 Days | 0 Days |
Enterprise Value | $795.68M | $11.02B |
Dividend Yield | 0.89% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
KKR's stock is trading at $85.60, down 6.46% in the last session amid a bearish technical outlook. The company maintains strong profitability with a 14.97% net income margin and has beaten earnings estimates in two of the last three quarters. Recent business developments include multiple strategic investments and joint ventures, including a partnership with Thomson Reuters and new equipment finance platform Akrapoint Commercial Capital.
Despite near-term price weakness, KKR presents a compelling investment case with strong analyst support (88.9% buy ratings) and a consensus price target of $123.20 representing 44% upside. Key risks include volatile cash flow patterns and high leverage, but the company's diversified investment platform and active deal pipeline support long-term growth prospects.
RGEN trades at $175.42, up 1.66% today, with a neutral technical signal and key support at $173. The stock has consistently beaten earnings estimates in recent quarters, with Q3 2026 results due October 27. Revenue grew to $738.26M in 2025, though net income margin is modest at 5.29%. The company recently completed the acquisition of BioLife Solutions, signaling strategic expansion.
Outlook remains positive with strong analyst support (91.67% buy ratings) and a consensus price target of $173.86, though high valuation multiples (P/E 240.34) pose a risk. Earnings growth and integration of acquisitions are key catalysts, but investors face execution risks and market volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About KKR & Co Inc
KKR is one of the world's largest alternative asset managers, with $490.7 billion in total assets under management, including $384.5 billion in fee-earning AUM, at the end of June 2022. The company has two core segments: asset management (which includes private markets--private equity, credit, infrastructure, energy and real estate--and public markets--primarily credit and hedge/investment fund platforms) and insurance (following the February 2021 purchase of a 61.5% economic stake in Global Atlantic Financial Group, which is engaged in retirement/annuity and life insurance lines as well as reinsurance). On the asset management side, private markets account for 50% of fee-earning AUM and 70% of base management fees, while public markets account for 50% and 30%, respectively.
Read more on KKR →About Repligen Corporation Common Stock
Repligen Corporation develops and manufactures bioprocessing tools and technologies used in biologic drug manufacturing, including filtration and perfusion systems, chromatography columns and resins, and process analytics instruments. Its products support upstream and downstream production workflows for modalities such as monoclonal antibodies, mRNA, and viral vectors.
Read more on RGEN →
